The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Tandem Meetings 2023 | Real-world outcomes of patients with transformed R/R DLBCL treated with CD19 CAR-T therapy
Swetha Kambhampati, MD, City of Hope, Duarte, CA, describes the rationale and findings from a single-center retrospective study evaluating standard of care CAR-T therapy in patients with relapsed/refractory (R/R) transformed diffuse large B-cell lymphoma (DLBCL). Overall, the study demonstrated that both safety and efficacy outcomes were comparable to those observed in patients with de novo DLBCL, thereby suggesting CAR-T therapy is a promising option in this population of high unmet medical need. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
